A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
Public ClinicalTrials.gov record NCT06411249. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.
Study identification
- NCT ID
- NCT06411249
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 303 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 6, 2024 (Actual)
- Primary completion
- Jun 29, 2027 (Estimated)
- Completion
- Jul 17, 2029 (Estimated)
- Last update posted
- Sep 1, 2026
2024 – 2029
United States locations
- U.S. sites
- 41
- U.S. states
- 14
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Flagstaff | Arizona | 86001 | — |
| GSK Investigational Site | Mesa | Arizona | 85210 | — |
| GSK Investigational Site | Tucson | Arizona | 85748 | — |
| GSK Investigational Site | Covina | California | 91722 | — |
| GSK Investigational Site | Fontana | California | 92335 | — |
| GSK Investigational Site | Fullerton | California | 92835 | — |
| GSK Investigational Site | Long Beach | California | 90720 | — |
| GSK Investigational Site | Los Angeles | California | 90211 | — |
| GSK Investigational Site | Mission Hills | California | 91345 | — |
| GSK Investigational Site | San Diego | California | 92128 | — |
| GSK Investigational Site | Temecula | California | 92592 | — |
| GSK Investigational Site | Tujunga | California | 91042 | — |
| GSK Investigational Site | Van Nuys | California | 92307-2333 | — |
| GSK Investigational Site | Van Nuys | California | 92586 | — |
| GSK Investigational Site | Whittier | California | 90602 | — |
| GSK Investigational Site | Aventura | Florida | 33180 | — |
| GSK Investigational Site | Clearwater | Florida | 33765 | — |
| GSK Investigational Site | Tamarac | Florida | 33321 | — |
| GSK Investigational Site | Tampa | Florida | 33606 | — |
| GSK Investigational Site | Atlanta | Georgia | 30152 | — |
| GSK Investigational Site | Morton Grove | Illinois | 60521 | — |
| GSK Investigational Site | Rockford | Illinois | 60123 | — |
| GSK Investigational Site | Baton Rouge | Louisiana | 70836 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70112 | — |
| GSK Investigational Site | Detroit | Michigan | 48202 | — |
| GSK Investigational Site | Lansing | Michigan | 48910 | — |
| GSK Investigational Site | Brooklyn | New York | 11201 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28202 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27157 | — |
| GSK Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Austin | Texas | 78745 | — |
| GSK Investigational Site | Baytown | Texas | 77521 | — |
| GSK Investigational Site | Colleyville | Texas | 76034 | — |
| GSK Investigational Site | Fort Worth | Texas | 76109 | — |
| GSK Investigational Site | Houston | Texas | 77089 | — |
| GSK Investigational Site | Katy | Texas | 77494 | — |
| GSK Investigational Site | Plano | Texas | 75024 | — |
| GSK Investigational Site | Danville | Virginia | 24541 | — |
| GSK Investigational Site | Glendale | Wisconsin | 53217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06411249, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06411249 live on ClinicalTrials.gov.